Revance Therapeutics, Inc. Announces Participation in 26th Annual Piper Jaffray Healthcare Conference
Revance management is scheduled to present on
About
Revance is a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. Revance is leveraging its proprietary portfolio of botulinum toxin compounds combined with its patented TransMTS® peptide delivery system to address unmet needs in the large and growing aesthetic and therapeutic botulinum toxin market. Revance’s proprietary TransMTS® technology enables transcutaneous delivery of botulinum toxin A, eliminating the need for injections. Revance’s lead product candidate, RT001, is a topical formulation of botulinum toxin type A, which has the potential to be the first commercially-available non-injectable dose form. RT001 is being evaluated in a broad clinical program that includes aesthetic indications such as crow’s feet lines (wrinkles around the
eyes) and therapeutic indications such as hyperhidrosis (excessive sweating). Revance’s second product candidate RT002, a novel injectable formulation of botulinum toxin type A designed to be more targeted and longer lasting than currently available botulinum toxin injectable products, is being evaluated in glabellar (frown) lines.
“Revance Therapeutics”, TransMTS® and the Revance logo are registered trademarks of
For more information, please visit: www.revance.com.
CONTACT:Westwicke Partners Leigh Salvo (415) 513-1281 leigh.salvo@westwicke.com
Source:
News Provided by Acquire Media
